

Disclosures

Personal Commercial (2)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Amgen Inc.	Research/Research Grants ‡ EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOlocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction	Significant (>= \$5,000)	Prevention
Novartis Pharmaceuticals	Research/Research Grants	Modest (< \$5,000)	Prevention

Additional Personal Commercial Disclosures for Education Activities (1)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Wake Forest School of Medicine	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (6)

Trial Name	Trial Sponsor	Trial Funding Source
S2317: Assessment of the WATCHMANTM Device in Patients Unsuitable for Oral Anticoagulation	Boston Scientific Corporation	
WaveCrest Vs. Watchman TransscEptal LAA Closure to REduce AF-Mediated STroke 2	Coherex Medical, Inc.	
1002-046: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER STUDY TO EVALUATE ... BEMPEDOIC ACID (ETC-1002) 180 MG COMPARED TO PLACEBO...IN... STATIN INTOLERANT (CLEAR)	Esperion Therapeutics, Inc.	
PRagmatic EVALuation of evENTs And Benefits of Lipid-lowering in oldEr adults (PREVENTABLE)	National Institutes of Health (NIH) (federal) and Patient-Centered Outcomes Research Institute	
Impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS]	Novartis Pharmaceuticals	
Cascade Screening for Awareness and Detection of Familial Hypercholesterolemia (CASCADE)	The FH Foundation	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/22/2023

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/22/2023

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

Embargo | Signed on 10/22/2023

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

On-Going Obligation Agreement | Signed on 10/22/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.